TRANSCATHETER HEART VALVE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Transcatheter Heart Valve Market Analysis & Forecast 

Transcatheter Heart Valve Market size is estimated to be valued at USD 6.77 Bn in 2026 and is expected to reach USD 17.03 Bn in 2033, exhibiting a compound annual growth rate (CAGR) of 14.1% from 2026 to 2033.

Key Takeaways

• By Product Type, the Transcatheter Mitral Valve Replacement (TMVR) segment is expected to lead the transcatheter heart valve market outlook with a projected 61% share in 2026.
• By Region, North America is projected to dominate the global transcatheter heart valve market with an estimated 40.9% share in 2026.

Market Overview

Increasing prevalence of aortic stenosis is expected to drive the global transcatheter heart valve market over the forecast period. For instance, in June 2021, an article published by BMJ Publishing Group Ltd, a publisher of medical journals, stated that the overall incidence rate of clinically significant aortic stenosis was 2.48 per 1000 person per year, and for moderate or severe aortic stenosis 4.05 per 1000 person per year.

Current Events and Its Impact on the Transcatheter Heart Valve Market

Pipeline Analysis

The transcatheter heart valve pipeline includes a diverse range of devices targeting aortic, mitral, and tricuspid valve replacements across multiple clinical phases.

• Preclinical/Early Development:
  Key aortic valve candidates include VitaFlow Liberty (MicroPort), Myval Octacor (Meril), and JenaValve Trilogy (Boston Scientific). For mitral valve replacement, notable projects are Tendyne (Abbott), Intrepid TMVR (Medtronic), and HighLife Transcatheter Mitral Valve.
• Phase I Trials:
  Devices like Portico FlexNav and NAVITOR (Abbott), Acurate neo2 (Boston Scientific), and AltaValve (4C Medical) are undergoing early clinical evaluation for safety and feasibility.
• Phase II Trials:
  Advancing candidates include ACURATE Prime (Boston Scientific), Evolut PRO+ (Medtronic), and EVOQUE (Edwards Lifesciences), targeting both aortic and tricuspid valve treatments.
• Phase III Trials:
  Market-ready devices include SAPIEN 3 Ultra (Edwards Lifesciences), Evolut FX (Medtronic), and MitraClip G4 (Abbott), with expanded indications for low-risk patients.
• Innovation Focus:
  Next-gen valves emphasize repositionability, reduced paravalvular leakage, enhanced durability, smaller delivery systems, and cerebral protection integration.

Several devices have CE Mark approval or FDA breakthrough designation, targeting wider patient populations and improved clinical outcomes.

Patent Landscape

The patent landscape in the transcatheter heart valve market is highly dynamic, reflecting intense innovation by leading medical device companies. Major players such as Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott hold a substantial portfolio of patents covering critical aspects including valve design, frame materials, delivery catheter technologies, and sealing mechanisms to minimize paravalvular leaks.

Recent patent filings emphasize advancements in biocompatible and durable materials aimed at extending valve lifespan, as well as innovations in repositionable and retrievable valve systems to enhance procedural safety and flexibility. Additionally, patents related to integrated imaging technologies and artificial intelligence-assisted placement are gaining prominence, aimed at improving accuracy and patient outcomes.

Geographically, patent activity is concentrated in the U.S., Europe, and select Asia-Pacific markets, aligning with major regulatory hubs and innovation centers. Emerging markets are witnessing gradual patent growth, signaling expanding research and development efforts.

Overall, the competitive patent environment underscores the market’s focus on technological differentiation and sustained product innovation, which are critical for maintaining competitive advantage and addressing unmet clinical needs.

Reimbursement Scenario

The reimbursement landscape for transcatheter heart valve (THV) procedures such as TAVR and TMVR varies globally, significantly influencing market access and adoption.

In the United States, key procedural CPT codes include 33361–33366 for various TAVR approaches and 33418–33419 for mitral valve repairs. Coverage decisions by Medicare (CMS) have progressively expanded from high-risk patients in 2012 to include intermediate and low-risk groups by 2019. Medicare reimburses these procedures under National Coverage Determination (NCD 20.32), requiring multidisciplinary heart team evaluations.

European countries follow ICD-10-GM and OPCS-4 coding systems, with reimbursement governed by national health technology assessment bodies such as NICE (UK), G-BA (Germany), and HAS (France). These agencies assess clinical and cost-effectiveness before approving coverage.

In the Asia-Pacific region, regulatory bodies including PMDA (Japan), NMPA (China), and TGA (Australia) oversee approvals and reimbursement policies, though coverage remains limited in many emerging markets due to cost constraints.

Overall, reimbursement remains a critical market driver, with expanding coverage and favorable coding facilitating greater adoption, while cost and regulatory complexity pose challenges in certain regions.

Prescribers’ Preference

Prescribers’ preferences in transcatheter heart valve interventions have evolved significantly, influenced by patient risk profiles, valve technology, and clinical evidence. For early-stage symptomatic aortic stenosis patients at low surgical risk, cardiologists and cardiac surgeons increasingly favor Transcatheter Aortic Valve Replacement (TAVR) as a first-line treatment, with Edwards Lifesciences’ SAPIEN 3 and Medtronic’s Evolut PRO+ series being the most commonly chosen devices.

In intermediate and high-risk patients, valve selection depends on anatomical complexity and comorbidities. For example, Edwards SAPIEN 3 Ultra is preferred for bicuspid valves, while Medtronic’s Evolut PRO+ is favored when pacemaker implantation risk is a concern. Abbott’s Portico is often chosen for severely calcified anatomies.

For valve-in-valve procedures in failed bioprosthetic valves, prescribers lean towards devices like SAPIEN 3 Ultra and JenaValve Trilogy for native aortic regurgitation.

Pharmaceutical management accompanying interventions includes dual antiplatelet therapy, anticoagulation for atrial fibrillation, and heart failure medications.

Overall, prescriber preferences reflect a balance of clinical trial data, patient-specific anatomy, and device features such as repositionability, durability, and ease of delivery.

Segmental Insights

Transcatheter Heart Valve Market Insights, By Product Type

Based on product type, the transcatheter mitral valve replacement (TMVR) segment is projected to dominate the market with a 61.0% share in 2026. This dominance is largely driven by the increasing adoption of TMVR for treating aortic stenosis and other mitral valve disorders.

TMVR offers a less invasive alternative to traditional surgical procedures, providing better patient outcomes and shorter recovery times, which fuels its growing preference among clinicians and patients alike. The transcatheter aortic valve replacement (TAVR) segment follows but is expected to hold a smaller share comparatively.

Transcatheter Heart Valve Market Insights, By Delivery System

The delivery systems segment is segmented into transfemoral approach, transapical approach, and transaortic approach. Among these, the transfemoral approach is anticipated to dominate the market during the forecast period. Its rise in preference is attributed to the increasing prevalence of cardiac disorders and the minimally invasive nature of this approach, which reduces procedural risks and improves patient recovery.

For example, a February 2020 article by the American Heart Association noted that although transfemoral access was traditionally considered secondary for TAVR, it is increasingly becoming the preferred primary route due to technological advancements and procedural efficacy.

Transcatheter Heart Valve Market Insights, By End User

In terms of end users, the hospitals segment is expected to dominate the market over the forecast period. This is due to a growing number of hospital admissions for transcatheter heart valve procedures, supported by enhanced cardiac care infrastructure and skilled interventional cardiologists. Other end users include ambulatory surgical centers and cardiac catheterization laboratories, which are also witnessing growth but on a smaller scale compared to hospitals.

Global Transcatheter Heart Valve Market- Regional Insights

North America Transcatheter Heart Valve Market Analysis and Trends

North America is projected to dominate the global transcatheter heart valve market, holding an estimated 40.90% share in 2026. This leadership is primarily driven by the rising prevalence of aortic stenosis and other valvular heart diseases across the region. Increasing awareness, advancements in minimally invasive cardiac procedures, and the presence of a well-established healthcare infrastructure further bolster market growth.

For instance, a January 2026 report by Guardian News & Media Limited highlighted that approximately 300,000 people in the U.K. suffer from potentially fatal aortic valve conditions, underscoring the region’s significant disease burden and demand for innovative treatment options.

Asia Pacific Transcatheter Heart Valve Market Analysis and Trends

Asia Pacific is anticipated to be the fastest growing market segment for transcatheter heart valves, driven by increasing cardiovascular disease incidence, growing geriatric populations, and improving healthcare access in countries such as China, India, Japan, and South Korea.

Government initiatives to enhance cardiac care infrastructure and expanding reimbursement coverage for advanced medical devices are key factors fueling market expansion. Additionally, rising patient awareness and adoption of minimally invasive interventions contribute to the rapid uptake of transcatheter valve technologies.

Dominating Countries in the Transcatheter Heart Valve Market

United States Transcatheter Heart Valve Market Analysis and Trends

The United States leads the North American market, supported by high healthcare expenditure, advanced cardiac care facilities, and early adoption of innovative transcatheter valve therapies. Strong clinical research activity and collaborations between medical device manufacturers and healthcare providers accelerate technology adoption and product launches.

China Transcatheter Heart Valve Market Analysis and Trends

China stands out in the Asia Pacific region due to its large patient pool, expanding healthcare infrastructure, and government policies aimed at improving cardiovascular devices accessibility. Increasing investments in domestic manufacturing and growing awareness about minimally invasive cardiac procedures are expected to drive significant market growth.

Market Report Scope

Global Transcatheter Heart Valve Market – Driver

• Increasing geriatric population

Transcatheter Heart Valve is mostly used to treat aortic stenosis, which occurs mostly in geriatric population, hence, increasing awareness campaign by key market players is expected to drive the transcatheter heart valve market over the forecast period. For instance, in October 2022, according to the World Health Organization (WHO), by 2030 the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion.

Global Transcatheter Heart Valve Market Cross Sectional Analysis:

In delivery systems segment, transfemoral approach hold a dominant segment in North America region due to the increasing prevalence of surgical site infection. For instance, on January 11 2023, according to report published by BioMed Central Ltd, an open access journal, stated that transfemoral approach is used mostly for transcatheter heart valve techniques.

Global Transcatheter Heart Valve Market: Key Trends

• Increasing prevalence of aortic stenosis

Increasing prevalence of aortic stenosis is expected to drive the transcatheter heart valve market growth over the forecast period. For instance, in March 2022, according to Edwards Lifesciences Corporation, a medical technology company, stated that for people over the age of 75 years, the prevalence of severe aortic stenosis is 3%.

Hence, increasing awareness of transcatheter heart valve devices may help in reducing the prevalence of aortic stenosis which will then help in the growth of the transcatheter heart valve market growth over the forecast period.

Analyst Viewpoint

• The transcatheter heart valve market is rapidly transforming cardiovascular treatment, driven by rising valvular heart disease prevalence and an aging global population. Its minimally invasive approach offers shorter recovery times and lower risks compared to traditional surgery, making it the preferred option for high-risk and elderly patients.
• Technological innovations in valve design, delivery systems, and imaging have improved procedural success and broadened patient eligibility. Next-generation valves with enhanced durability and minimized leakage are fueling increased adoption worldwide.
• Challenges include high procedural costs, limited reimbursement in emerging markets, and the need for specialized training and infrastructure. Regulatory hurdles can also delay new product introductions.
• North America leads the market, backed by advanced healthcare infrastructure and supportive reimbursement policies. Meanwhile, the Asia-Pacific region is the fastest-growing market due to improving healthcare access, rising incomes, and greater awareness of advanced therapies.
• Growth opportunities lie in expanding indications to younger, lower-risk patients and penetrating emerging markets. Additionally, integrating artificial intelligence for procedural planning and developing fully repositionable valves offer significant potential for improving outcomes and expanding market reach.

Global Transcatheter Heart Valve Market: Key Developments

• In May 2025, Edwards Lifesciences launched its next-generation transcatheter aortic valve system, featuring enhanced durability and a repositionable design, targeting expanded use in low-risk patients.
• In April 2025, Medtronic received FDA approval for its innovative transcatheter mitral valve repair device, marking a significant milestone in minimally invasive mitral valve therapies.
• In March 2025, Boston Scientific entered a strategic collaboration with leading cardiac centers to implement AI-driven imaging technology aimed at improving valve sizing accuracy and procedural outcomes.
• In February 2025, Abbott expanded its presence in emerging markets by obtaining regulatory clearance for its transcatheter tricuspid valve system in India and Brazil.
• In January 2025, the U.S. National Institutes of Health (NIH) awarded $45 million in grants to support clinical trials focused on long-term outcomes of transcatheter heart valve therapies in elderly populations.

Market Segmentation

• Global Transcatheter Heart Valve Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
  • TAVR
  • TMVR
• Global Transcatheter Heart Valve Market, By Delivery Systems (Revenue, USD Bn, 2021 - 2033)
  • Transfemoral Approach
  • Transapical Approach
  • Transaortic Approach
• Global Transcatheter Heart Valve Market, By End User (Revenue, USD Bn, 2021 - 2033)
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratory
  • Other (Specialty Center, etc.)
• Global Transcatheter Heart Valve Market, By Region (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Company Profiles
  • Edwards Lifesciences Corporation
  • Medtronic
  • Boston Scientific Corporation
  • Abbott, JenaValve Technology
  • SYMETIS
  • Braile Biomedica
  • CryoLife, Inc.
  • Shockwave Medical Inc.
  • Venus Medtech (Hangzhou) Inc.

Sources

Primary Research Interviews

• Interventional Cardiologists
• Cardiac Surgeons
• Medical Device Manufacturers
• Hospital Procurement Managers
• Others

Databases

• FDA Medical Device Database
• ClinicalTrials.gov
• MAUDE (FDA Adverse Event Reporting)
• Global Health Observatory (WHO)
• Others

Magazines

• Cardiovascular Business
• Medical Device and Diagnostic Industry (MDDI)
• Cardiology Today
• Interventional Cardiology Review
• Others

Journals

• Journal of the American College of Cardiology
• Circulation Cardiovascular Interventions
• EuroIntervention Journal
• Others

Newspapers

• Financial Times
• The Wall Street Journal
• Reuters Health News
• Bloomberg Healthcare
• Others

Associations

• American College of Cardiology (ACC)
• Society for Cardiovascular Angiography and Interventions (SCAI)
• European Society of Cardiology (ESC)
• Heart Valve Voice
• Others

Public Domain Sources

• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• National Heart, Lung, and Blood Institute (NHLBI)
• European Medicines Agency (EMA)
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years